Delivery Order SPE2DB22D2206-SPE2DB24FGR64
- Not listed
- This federal contract award to AmerisourceBergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product NEUPOGEN 300 MCG/ML VIALML to the Defense Logistics Agency (DLA), a defense agency under the Department of Defense (DoD). The contract is a Firm Fixed Price Delivery Order valued at $1,944.43, with a completion date of June 28, 2024. The contract is not set aside and was awarded on a full and open competition basis. AmerisourceBergen, a major pharmaceutical...
- This federal contract award, valued at $3,644.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order for the supply of the medication NEUPOGEN 300 MCG/ML VIALML, with an ultimate completion date of April 17, 2025. The contract is a firm fixed-price, non-set-aside arrangement. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense, to Amerisourcebergen Drug Corp's Corporate Office Division. The $7,654.79 Firm Fixed Price Delivery Order is for the supply of NEUPOGEN 300 MCG/ML, a prescription medication, with a completion date of June 28, 2024. Amerisourcebergen is a major pharmaceutical distribution company that holds Indefinite Delivery Contracts (IDCs) with both the DLA, valued up to...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a Delivery Order valued at $1,122.42 for the supply of the pharmaceutical product NEUPOGEN 480 MCG/0.8 ML SYR 0.8ML. The contract has an ultimate completion date of May 16, 2024 and a firm fixed price pricing type. The award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the Defense Logistics Agency (DLA) Troop Support Medical, valued at up to $999,999,999.00...
- This federal contract award, valued at $3,644.34, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the NEUPOGEN 300 MCG/ML VIALML product, with a firm fixed price and an ultimate completion date of June 11, 2025. AmerisourceBergen Drug Corp, a for-profit organization, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is for the delivery of a wide range of pharmaceutical products and medical supplies to the U.S. government. The contract, valued at $267,654.00, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen's Corporate Office Division. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued up to $999,999,999.00 through...
- This federal contract award, valued at $83,765.48, was made to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen to deliver a...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical supplier, provides a range of medical products and prescription drugs to the U.S. Department of Defense (DoD) and other government agencies. The contract, valued at $10,547.86, is a firm-fixed price delivery order with a completion date of July 9, 2024. It is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of pharmaceutical products and medical supplies to the U.S. government. The $1,878.35 Firm Fixed Price Delivery Order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, which is part of the Department of Defense (DoD). Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at up to $999,999,999.00 through December 31, 2025, to...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of pharmaceutical products and medical supplies to the U.S. Department of Defense (DoD) and other government agencies. The $1,182.71 Firm Fixed Price Delivery Order has an ultimate completion date of August 5, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FGR64Delivery Order
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of Amerisourcebergen Corporation, is for the delivery of NEUPOGEN 300 MCG/ML VIALML pharmaceutical products. The contract, valued at $8,527.28, was awarded by the Defense Logistics Agency (DLA), a defense agency, on April 15, 2024 with a completion date of April 16, 2024. The contract is a firm fixed-price delivery order with no set-aside designation. Amerisourcebergen, a major pharmaceutical distribution company, holds several Indefinite Delivery Contracts (IDCs) with federal agencies, including a $999,999,999.00 single-award IDC with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 4/15/24 |